Form 4: PepGen Director Howard Mayer Acquires 16,000 Stock Options

PepGen Inc. Director Howard Mayer has acquired 16,000 stock options with an exercise price of $1.51, set to vest within one year or by the next Annual Meeting.

Summary

• Howard Mayer, a Director of PepGen Inc. (PEPG), acquired 16,000 stock options on June 4, 2025.
• The stock options have an exercise price of $1.51 per share.
• These options are for 16,000 shares of PepGen Inc. common stock.
• The options are scheduled to vest in full upon the earlier of June 4, 2026 (the first anniversary of the grant date) or the date of the next Annual Meeting.
• Vesting is contingent on Mr. Mayer's continued service as a director, unless the Board of Directors determines that circumstances warrant continuation of vesting.
• The stock options have an expiration date of June 3, 2035.
• Following this transaction, Mr. Mayer directly beneficially owns 16,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management/director interests with shareholders, but it's a routine compensation event rather than a major strategic announcement.

Positives

• The acquisition of stock options by a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• The long expiration date of June 3, 2035, provides a substantial window for the options to potentially gain value if the company's stock price appreciates.

Risks

• The vesting of the stock options is conditional on Howard Mayer's continued service as a director; if he ceases to serve, vesting will cease unless otherwise determined by the Board.
• The value of the stock options is dependent on PepGen Inc.'s common stock price exceeding the exercise price of $1.51 per share in the future.

Future Outlook

The stock options granted to Director Howard Mayer are set to vest on the earlier of June 4, 2026, or the date of the next Annual Meeting, provided he continues his service as a director.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, reporting changes in beneficial ownership by insiders. Granting stock options to directors is a common practice across industries, including biotechnology, to align their incentives with long-term shareholder value creation and retain talent.

Comparison to Industry Standards

• Granting stock options to non-executive directors is a standard practice across various industries, including biotechnology, to align their interests with long-term shareholder value. The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with shareholder value creation.

Next Steps

• Continued service of Howard Mayer as a director for the vesting conditions of the options to be met.
• Potential future exercise of the options by Howard Mayer, contingent on PepGen Inc.'s stock price performance.

Key Dates

Keywords

PepGen Inc., PEPG, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Howard Mayer